Hims & Hers Health Inc. (NYSE:HIMS) on Monday posted downbeat third-quarter fiscal 2026 results. 

Hims & Hers Health reported quarterly losses of 14 cents per share, which missed the analyst estimate of earnings of eight cents, per Benzinga Pro data. Quarterly revenue of $890.37 million missed the Street estimate of $892.89 million, but was up from $598.98 million in the same period last year.

"In health care, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them," said Andrew Dudum, co-founder and CEO.

Hims & Hers Health expects fourth-quarter revenue in a range of $875 million to $895 million, versus the $953.45 million analyst estimate. The company narrowed its fiscal 2026 revenue outlook to between $3.13 billion and $3.15 billion, versus the $3.21 billion estimate.

Hims & Hers Health shares fell 13.3% to trade at $19.86 on Tuesday.

These analysts made changes to their price targets on Hims & Hers Health following earnings announcement.

• Needham analyst Ryan MacDonald maintained the stock with a Buy and lowered the price target from $42 to $32.
• Evercore ISI Group analyst Mark Mahaney maintained the stock with an In-Line rating and raised the price target from $24 to $27.

Considering buying HIMS stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.